Reduced NMN Can Boost NAD+ by 10X Safety Validated

Overview

Reduced-NMN-Can-Boost-NAD-by-10X-Safety-Validated.png

NMNH refers to the reduced form of NMN. Preclinical studies show that NMNH demonstrates a remarkable 10X surge in NAD+ levels.

UthPeak™, EffePharm's pioneering NMNH product, received significant attention during Vitafoods Europe 2024. UthPeak™ has completed rigorous toxicology and efficacy tests, proving its safety and benefits for anti-aging, anti-fatigue, and cardiovascular health.

UthPeak™ is currently conducting a phase I clinical trial, with results expected by the end of 2024. UthPeak™ NMNH finished products are available to purchase on Amazon.

Download the file now to learn more.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Related Topics

IngredientsHealth

Latest Content

Related Resources

The Global Regulatory Advantage Behind UTHEVER® NMN

The Global Regulatory Advantage Behind UTHEVER® NMN

Paid for by Effepharm Ltd

White Paper

Regulatory uncertainty remains one of the biggest challenges for NMN brands. Choosing the wrong ingredient could lead to compliance risks & market restrictions.

Discover UTHEVER® NMN’s Global Regulatory Landscape

Discover UTHEVER® NMN’s Global Regulatory Landscape

Paid for by Effepharm Ltd

White Paper

NMN has long faced regulatory challenges. Today, that landscape is changing. We consistently invest in scientific research & quality development, aiming to establish UTHEVER® as the world’s most compliant NMN ingredient brand.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.